Clinical trials
Open Label clinical trials
Below are recruiting open label clinical trials, each written for real people, not researchers. We’re tracking 370 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07091175RecruitingPhase 2
Dupilumab for nephrotic syndrome in children
This trial tests if dupilumab can help children with nephrotic syndrome who still have relapses despite standard treatments. It aims to find a better way to control the disease and reduce steroid side effects.
Singapore, SingaporeAges 6–18 - NCT06968364Recruiting
Testing a device to predict preterm birth risk
This trial tests a new medical device to see if it can help predict preterm birth in pregnant women who are having early contractions. It may help doctors decide which patients need treatment to prevent early delivery.
A CoruñaAges 18 years+ - NCT07373210Recruiting
Placebo pills for hip surgery pain in teens and young adults
This study tests whether taking placebo pills (pills with no active drug) can help manage pain after a specific hip surgery, called Bernese Periacetabular Osteotomy (PAO), in people with a hip condition called developmental dysplasia. The goal is to see if using placebos can reduce the need for pain medications and help with recovery.
San Francisco, CaliforniaAges 13–40 - NCT06365892Recruiting
Open-label placebo for pain after scoliosis surgery
This trial tests whether taking a placebo pill that you know is a placebo (open-label placebo) can help reduce pain after spinal fusion surgery for scoliosis. It compares the placebo to standard care in adolescents aged 11-17.
San Francisco, CaliforniaAges 10–18 - NCT07633756RecruitingPhase 1
Testing RB1-negative Leiomyosarcoma Treatment with REC-617
This study tests a new drug called REC-617 in patients with a rare muscle cancer (leiomyosarcoma) that has spread or cannot be surgically removed. The drug targets cancer cells that lack a specific protein called RB1, and you must have already tried at least one other cancer treatment before joining.
Houston, TexasAges 18 years+ - NCT07735377RecruitingPhase 1
Study of SHR-6914 for Prostate Cancer
This study tests a new drug called SHR-6914 in men with prostate cancer that has spread. The goal is to see if it is safe and helps shrink or control the cancer, and to learn how the body processes it.
Guangzhou, GuangdongAges 18–80 - NCT06664814RecruitingPhase 2
Study of ManNAc for primary FSGS
This trial tests an investigational drug called ManNAc for people with a specific kidney disease called FSGS that causes protein in the urine. The goal is to see if ManNAc can help reduce protein loss and slow kidney decline.
Bethesda, MarylandAges 18–115 - NCT07008469Enrolling by invitationPhase 3
Long-term safety study of del-desiran for DM1
This study tests whether the drug del-desiran continues to be safe and effective for people with DM1 (myotonic dystrophy type 1) after they complete an earlier study. You'll receive the drug and have regular check-ups to see how you're doing.
Los Angeles, CaliforniaAges 16 years+ - NCT07456891RecruitingPhase 3
Long-term access to remibrutinib for skin or allergy patients
This trial provides ongoing access to remibrutinib for people who were previously in a Novartis study and are still benefiting from the drug. It is for those who cannot get the marketed version yet.
SofiaAges 18–100 - NCT07773883Enrolling by invitationPhase 3
Long-term safety of solriamfetol for ADHD in children and teens
This study checks the long-term safety of the drug solriamfetol for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents who have already completed an earlier study of this medication.
Dothan, AlabamaAges 6–18 - NCT07504458RecruitingPhase 3
Study of QTX-2101 for adults with a type of leukemia
This trial tests a new drug, QTX-2101, in people with acute promyelocytic leukemia (APL) that is low- or intermediate-risk. The study aims to see if the drug works and is safe for those who qualify.
Birmingham, AlabamaAges 18–71 - NCT07206056RecruitingPhase 1/Phase 2
Study of tulmimetostat and luxdegalutamide for advanced prostate cancer
This trial tests a new combination of two drugs for men whose prostate cancer has spread and is no longer controlled by hormone therapy. The study aims to see if this treatment can help shrink tumors or slow the disease.
Denver, ColoradoAges 18 years+ - NCT07226986RecruitingPhase 1/Phase 2
Study of AMO959 with Lutetium-177 and ARPI for prostate cancer
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT04638647RecruitingPhase 4
Continue secukinumab after prior study, without safety issues
This trial lets people who already did a previous secukinumab (an injection for certain inflammatory conditions) study continue treatment afterward. It’s mainly for people who are still getting benefit and can’t otherwise get the approved medication through their local system.
Fullerton, CaliforniaAges 6–100 - NCT06991556RecruitingPhase 2
Testing JSB462 plus abiraterone for advanced prostate cancer
This trial tests a new drug called JSB462 combined with abiraterone in men with prostate cancer that has spread to other parts of the body and is still responding to hormone therapy. The goal is to see if this combination works better than current treatments.
La Jolla, CaliforniaAges 18 years+ - NCT06616766RecruitingPhase 1/Phase 2
Study of YH42946 for advanced cancer with HER2 or EGFR changes
This trial tests a new drug (YH42946) in people with advanced solid tumors that have specific changes in HER2 or EGFR genes and have stopped responding to standard therapies. The drug aims to target these genetic changes to slow or shrink the cancer. Participants will be monitored closely for safety and how well the drug works.
Fairfax, VirginiaAges 18 years+ - NCT06328777RecruitingPhase 2/Phase 3
Testing a new immune cell therapy for systemic sclerosis (scleroderma)
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
New Haven, ConnecticutAges 18–75 - NCT06858319RecruitingPhase 3
Long-term study of zigakibart for IgA nephropathy
This study is for people with IgA nephropathy who completed a previous zigakibart study. It tests whether continuing treatment with zigakibart (given as a shot every two weeks) is safe and helpful over a longer period.
Denver, ColoradoAges 18–100 - NCT07161700Enrolling by invitationPhase 2
Long-term safety study of SPT-300 for major depression
This study is for people who finished the earlier BUOY-1 study of SPT-300 and want to continue treatment. It tests the long-term safety and tolerability of SPT-300 for major depressive disorder, with or without anxious distress.
Chino, CaliforniaAges 18–66 - NCT07570862RecruitingPhase 2
CAR T-Cell Therapy for Hard-to-Treat Lupus Kidney Disease
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
Beverly Hills, CaliforniaAges 12–70 - NCT07426757RecruitingPhase 1
A study of PF-07994525 for advanced multiple myeloma
This trial tests an experimental drug, PF-07994525, for people with advanced multiple myeloma that has not responded to or could not tolerate at least 3 prior treatments. The goal is to see if it can help control the cancer.
Coral Gables, FloridaAges 18 years+ - NCT06344416Recruiting
Ribociclib adherence study with smart pill dispenser
This study is testing a new smart pill dispenser (called ReX) to help people with advanced breast cancer take their ribociclib medication regularly. You will answer simple questions about how you feel, and the device will track your medication use.
Minneapolis, MinnesotaAges 18 years+ - NCT06255782RecruitingPhase 3
Gene therapy study for baby boys with severe OTC deficiency
This trial tests a gene therapy called ECUR-506 for baby boys under 9 months old with a severe form of OTC deficiency. The goal is to see if it can help their bodies process ammonia better, reducing the need for a strict protein-restricted diet and medications.
Los Angeles, CaliforniaAges 1 day–7 months - NCT07234032RecruitingPhase 3
Long-term follow-up study of TPIP for PH-ILD
This trial is a long-term follow-up study for people who already completed a previous study of an inhaled treprostinil medication (TPIP) for pulmonary hypertension caused by interstitial lung disease (PH-ILD). It tests whether continued treatment with TPIP is safe and effective over a longer period.
Naples, FloridaAges 18 years+
Hear when a new Open Label trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for open label?
- Yes. Clin2 currently lists 370 recruiting open label studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a open label trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a open label trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.